165 related articles for article (PubMed ID: 28692770)
1. Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.
Ghiti Moghadam M; Ten Klooster PM; Vonkeman HE; Kneepkens EL; Klaasen R; Stolk JN; Tchetverikov I; Vreugdenhil SA; van Woerkom JM; Goekoop-Ruiterman YPM; Landewé RBM; van Riel PLCM; van de Laar MAFJ; Jansen TL;
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):516-524. PubMed ID: 28692770
[TBL] [Abstract][Full Text] [Related]
2. Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.
Ghiti Moghadam M; Vonkeman HE; Ten Klooster PM; Tekstra J; van Schaardenburg D; Starmans-Kool M; Brouwer E; Bos R; Lems WF; Colin EM; Allaart CF; Meek IL; Landewé R; Bernelot Moens HJ; van Riel PL; van de Laar MA; Jansen TL;
Arthritis Rheumatol; 2016 Aug; 68(8):1810-7. PubMed ID: 26866428
[TBL] [Abstract][Full Text] [Related]
3. Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.
Plasencia C; Wolbink G; Krieckaert CL; Kneepkens EL; Turk S; Jurado T; Martínez-Feito A; Navarro-Compán V; Bonilla G; Villalba A; Peiteado D; Nuño L; Martín-Mola E; Nurmohamed MT; van der Kleij D; Rispens T; Pascual-Salcedo D; Balsa A
Clin Exp Rheumatol; 2016; 34(4):655-62. PubMed ID: 27214767
[TBL] [Abstract][Full Text] [Related]
4. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
5. Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.
Lamers-Karnebeek FB; Luime JJ; Ten Cate DF; Teerenstra S; Swen NWAA; Gerards AH; Hendrikx J; van Rooyen EM; Voorneman R; Haagsma C; Basoski N; de Jager M; Ghiti Moghadam M; Efde MN; Goekoop-Ruiterman YPM; van Riel PLCM; Jacobs JWG; Jansen TL
Rheumatology (Oxford); 2017 Sep; 56(9):1560-1565. PubMed ID: 28595367
[TBL] [Abstract][Full Text] [Related]
6. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
9. An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
Tran-Duy A; Ghiti Moghadam M; Oude Voshaar MAH; Vonkeman HE; Boonen A; Clarke P; McColl G; Ten Klooster PM; Zijlstra TR; Lems WF; Riyazi N; Griep EN; Hazes JMW; Landewé R; Bernelot Moens HJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
Arthritis Rheumatol; 2018 Oct; 70(10):1557-1564. PubMed ID: 29745059
[TBL] [Abstract][Full Text] [Related]
10. Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.
Ghiti Moghadam M; Lamers-Karnebeek FBG; Vonkeman HE; Ten Klooster PM; Tekstra J; Schilder AM; Visser H; Sasso EH; Chernoff D; Lems WF; van Schaardenburg DJ; Landewe R; Bernelot Moens HJ; Radstake TRDJ; van Riel PLCM; van de Laar MAFJ; Jansen TL;
PLoS One; 2018; 13(5):e0192425. PubMed ID: 29791439
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
Vanier A; Mariette X; Tubach F; Fautrel B;
Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the expediency of TNFi in rheumatoid arthritis: offering a TNFi holiday in patients having reached low-disease activity in the maintenance phase.
van Ingen IL; Lamers-Karnebeek F; Jansen TL
Expert Opin Biol Ther; 2014 Dec; 14(12):1761-7. PubMed ID: 25366268
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
[TBL] [Abstract][Full Text] [Related]
17. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs.
Rongen GA; van Ingen I; Kok M; Vonkeman H; Janssen M; Jansen TL
Clin Rheumatol; 2018 Apr; 37(4):909-916. PubMed ID: 29307093
[TBL] [Abstract][Full Text] [Related]
18. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
